ClinicaliQ Trial Snapshot
- Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) — Active Not Recruiting • Phase II • Oncology • NCT03134118.
- Nivolumab showed activity and tolerable side-effects in previously-treated thymic carcinoma and B3 thymoma patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The aim of the phase II Nivothym study is to collect data on activity and toxicity of nivolumab therapy in patients with thymic carcinoma or type B3 thymoma that previously received a first platinum-based chemotherapy. Conditions: Thymoma Type B3, Thymic Carcinoma Interventions: Nivolumab Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC Planned Enrollment: 55 participants